GLP1R and inflammatory bowel disease: While GLP-1R agonists represent promising therapeutic agents due to their anti-inflammatory and regenerative properties, their potential to further impair intestinal motility and worsen constipation must be considered, particularly in IBD patients prone to slow transit.